November 3, 2015
Janssen Applys to EMA to Expand Use of Imbruvica
Janssen-Cilag International NV announced on Tuesday the submission of a Type II variation application to the European Medicines Agency (EMA) seeking…
Pharmaceuticals, Biotechnology and Life Sciences
Janssen-Cilag International NV announced on Tuesday the submission of a Type II variation application to the European Medicines Agency (EMA) seeking…